Wells Fargo Maintains Equal-Weight on Pfizer, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) but lowered the price target from $39 to $35.
October 17, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Pfizer but lowered the price target from $39 to $35.
The lowering of the price target by Wells Fargo indicates a potential decrease in Pfizer's stock price in the short term. This is likely to negatively impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100